Search
Gossamer Bio Inc
GOSSAdd to Watchlist
0.168USD
+0.003+1.88%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
81.98MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.88%
5 Days
-0.77%
1 Month
-15.35%
6 Months
-94.59%
Year to Date
-94.59%
1 Year
-86.58%
Key Figures
0.167Open
0.170High
11.74MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
5.02%Turnover Ratio
0.165Prev. Close
0.163Low
1.43MTurnover
LossP/E Static
-0.32P/B
0.00%Div Yield TTM
-88.11%ROA
3.87052wk High
0.66Volume Ratio
-56.53MNet Profit
233.68MShares
-0.7833EPS TTM
2.02Beta
-783.37%ROE
0.16352wk Low
4.31%Amplitude
100.00%Gross Margin
81.98MMarket Cap
-2.73Reward/Risk
6.51%Risk Rate
TradingKey Stock Score of Gossamer Bio Inc
Currency: USD Updated: 2026-07-01Key Insights
Gossamer Bio Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 102 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 4.71.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Gossamer Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Gossamer Bio Inc Highlights
StrengthsRisks
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
Growing
The company is in a growing phase, with the latest annual income totaling USD 48.47M.
Overvalued
The company’s latest PE is -0.21, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 172.23M shares, decreasing 20.77% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 173.47K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.29.
Analyst Rating
Based on
8
analysts
Hold
Current Rating
4.713
Target Price
+2763.51%
Upside Space
Gossamer Bio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Gossamer Bio Inc Info
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
Ticker SymbolGOSS
CompanyGossamer Bio Inc
CEOHasnain (Faheem)
Websitehttps://www.gossamerbio.com/
Related Instruments
-0.64%
-0.05%
-0.23%
-1.64%
-2.41%
-2.95%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52283.200
+28.900 (+0.06%)
29667.500
-131.800 (-0.44%)
7476.400
+0.900 (+0.01%)
14791.000
-564.000 (-3.67%)
68549.000
-936.000 (-1.35%)
6290.000
+14.600 (+0.23%)
68.024
+0.056 (+0.08%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4072.740
+41.970 (+1.04%)
FAQs
What is the current price of Gossamer Bio Inc (GOSS)?
The current price of Gossamer Bio Inc (GOSS) is 0.17.
What is the symbol of Gossamer Bio Inc?
The ticker symbol of Gossamer Bio Inc is GOSS.
What is the 52-week high of Gossamer Bio Inc?
The 52-week high of Gossamer Bio Inc is 3.87.
What is the 52-week low of Gossamer Bio Inc?
The 52-week low of Gossamer Bio Inc is 0.16.
What is the market capitalization of Gossamer Bio Inc?
The market capitalization of Gossamer Bio Inc is 39.19M.
Is Gossamer Bio Inc (GOSS) currently rated as Buy, Hold, or Sell?
According to analysts, Gossamer Bio Inc (GOSS) has an overall rating of signal_hold, with a price target of 4.71.
What is the Earnings Per Share (EPS TTM) of Gossamer Bio Inc (GOSS)?
The Earnings Per Share (EPS TTM) of Gossamer Bio Inc (GOSS) is -0.75.